Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Why Lilly (LLY) International Revenue Trends Deserve Your Attention
10:21am, Tuesday, 13'th May 2025
Examine Lilly's (LLY) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared
08:40am, Tuesday, 13'th May 2025
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.
NVO, PFE and LLY Forecast – Pharma Stocks React to Drug Order Trump Signs
08:40am, Tuesday, 13'th May 2025
The executive order that Donald Trump has signed over the last 24 hours could have a significant effect on pharmaceutical companies, and as a result, we should be paying attention to this sector.
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
06:25pm, Monday, 12'th May 2025
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies,
Trade Tracker: Stephanie Link sells Eli Lilly and buys more Intuitive Surgical
01:21pm, Monday, 12'th May 2025
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Drugmakers are spared worst-case drug pricing scenario for now
01:14pm, Monday, 12'th May 2025
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
12:36pm, Monday, 12'th May 2025
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
12:30pm, Monday, 12'th May 2025
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in obesity drug trial
10:46am, Monday, 12'th May 2025
Eli Lilly and Co (NYSE:LLY)'s weight loss drug Zepbound (tirzepatide) has shown superior results compared to Novo Nordisk (NYSE:NVO)'s Wegovy (semaglutide) in a direct clinical trial, marking the firs
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
10:41am, Monday, 12'th May 2025
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy
09:12am, Monday, 12'th May 2025
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (May 2025)
08:25am, Monday, 12'th May 2025
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Pfizer, Eli Lilly, Other Pharma Stocks Fall as Trump Targets Lower Drug Prices
07:10am, Monday, 12'th May 2025
Trump said he would lower the cost of medicines for Americans by between 30% and 80%.
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
06:06pm, Sunday, 11'th May 2025
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.
Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist cir
